New Diagnostic Ultrasound System Set to Disrupt Transient Elastography Market

Every year, millions of adults receive a chronic liver disease or cirrhosis diagnosis, and a significant number of fatalities occur due to liver disease. Now, a unique solution utilizes real-time 2D ultrasound combined with Visual Transient Elastography (ViTE), thereby providing an optimal solution for detecting, quantifying, and evaluating liver fibrosis and steatosis.

Mindray (Shenzhen, China) has made its foray into the transient elastography market with the introduction of the Hepatus 6 Diagnostic Ultrasound System. This system combines transient elastography and diagnostic ultrasound into a single device, making it perfectly adaptable for non-invasive detection, diagnosis, and assessment of liver disease. Mindray's innovative technology in liver care offers healthcare professionals a comprehensive solution for non-invasive liver disease management employing transient elastography. The Hepatus 6 System boasts a new set of quantitative tools designed for evaluating liver disease, offering clinicians a user-friendly and dependable solution for diagnosing liver fibrosis and steatosis.

"The global elastography imaging industry generated USD 3 billion in 2021 and is expected to grow to USD 6 billion by 20312, with much of this growth fueled by the rise in the prevalence of chronic liver diseases," said Wayne Quinn, President of Mindray North America. "The Hepatus 6 System provides clinicians a clear view of patient liver health and helps create a clear path forward for patients with chronic liver diseases, like no other system on the market today. We are excited to bring this offering to clinicians to help them provide better healthcare for all."

Related Links:
Mindray